The Effect of Daily Consumption of Extra Virgin Olive Oil on Blood Glucose Among Diabetic Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03447301|
Recruitment Status : Not yet recruiting
First Posted : February 27, 2018
Last Update Posted : February 27, 2018
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes Mellitus||Dietary Supplement: Extra virgin olive oil (30mL daily)||Not Applicable|
Problem: Saudi Arabia has the highest prevalence (24%) of type 2 diabetes mellitus (T2DM) among the modern nation states in the world. In addition, majority of Saudi diabetic patient do not have their blood glucose controlled.
Significance: Data suggests that diet, rich in olive oil and nuts, significantly reduces fasting plasma glucose and HbA1c (glycated hemoglobin). Olive oil has been associated with weight reduction as well as improvements in lipid profile (increase in high density (HDL) and decrease in low-density lipoprotein (LDL)). No randomized controlled trial has specifically examined the effect of olive oil as a supplement on blood glucose among diabetics.
Objectives: To test the effect of daily consumption (30 mL) of extra-virgin olive oil (EVOO) on HbA1c among patients with type 2 diabetes.
Methods: The study design will be an open-label randomized controlled trial with 2 groups (EVOO versus no oil). The study will include 420 patients and each patient will be followed for 3 months. Group difference in HbA1c will be compared at 3 months to determine the effect of EVOO.
Implications: Dietary supplementation of EVOO could aid Saudi diabetic patients in keeping blood glucose levels controlled.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||400 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Effect of Daily Consumption of Extra Virgin Olive Oil on Blood Glucose Among Diabetic Patients: An Open-label Parallel Group Randomized Controlled Trial.|
|Estimated Study Start Date :||February 25, 2018|
|Estimated Primary Completion Date :||August 25, 2018|
|Estimated Study Completion Date :||December 25, 2018|
Experimental: Extra virgin olive oil
Extra virgin olive oil (30mL) daily
Dietary Supplement: Extra virgin olive oil (30mL daily)
Intervention arm will take 30 mL of Extra virgin olive oil daily.
No Intervention: Control
No consumption of extra virgin olive oil
- HbA1c (glycated hemoglobin) [ Time Frame: 3-month follow-up ]
- Fasting Plasma Glucose [ Time Frame: 3-month follow-up ]
- Lipid Profile [ Time Frame: 3-month follow-up ]High-density lipoprotein (HDL), Low-density lipoprotein (LDL), HDL/LDL ratio, triglycerides (TG), Cholesterol
- Weight [ Time Frame: 3-month follow-up ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03447301
|Contact: Nazmus Saquib, PhD||966 firstname.lastname@example.org|
|Contact: Juliann Saquib, PhD||966 email@example.com|
|Buraidah Diabetic Center||Not yet recruiting|
|Buraidah, Al-Qassim, Saudi Arabia, 52366|
|Contact: Saddik Zaghoul, MBBS firstname.lastname@example.org|
|Principal Investigator:||Nazmus Saquib, PhD||Sulaiman Al-Rajhi Colleges|